Research Information System
European Journal of Pediatrics, vol.185, no.6, 2026 (SCI-Expanded, Scopus)
Linezolid is commonly used in children for the treatment of severe gram-positive infections; however, data on metabolic adverse effects remain limited. We evaluated lactate abnormalities in pediatric patients receiving intravenous linezolid. Among 215 children, hyperlactatemia/lactic acidosis occurred in 55.8%. Hyperlactatemia and/or lactic acidosis tended to develop early after treatment initiation and was more frequently observed in younger children and in those with complex underlying conditions, including neurometabolic and hemato-oncologic disorders. These findings suggest that host-related factors may influence susceptibility to lactate disturbances during linezolid therapy and support careful clinical monitoring in selected pediatric populations.